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ABSTRACT
Recent years have witnessed the emergence of novel methicillin-resistant Staphylococcus aureus (MRSA)
strains that produce the potent toxin Panton–Valentine leukocidin (PVL). PVL-positive strains can cause
complicated skin infections or necrotising pneumonia with high mortality, and these strains have the
potential for epidemic spread in the community. In 2004–2005, two case clusters and two isolated cases
were observed in eastern Saxony and southern Brandenburg. These were the first known infections with
PVL-positive community-acquired MRSA (caMRSA) in this part of Germany. The isolates belonged to
agr type III, spa type 44 or spa type 131, and showed a SmaI macrorestriction pattern that corresponded to
caMRSA of clonal group ST80. The isolates were susceptible to levofloxacin, macrolides, clindamycin,
gentamicin and vancomycin. Most isolates showed resistance to tetracycline and fusidic acid because of
the presence of the tetK and far1 genes. A novel plasmid (designated pUB102) harbouring far1, tetK and
blaZ was characterised and partially sequenced. Microarray analysis revealed that the caMRSA isolates
harboured genes encoding several bi-component toxins (lukF ⁄ S-PVL, lukD ⁄E, lukS ⁄F plus hlgA, and
another putative leukocidin homologue). Neither tst1 nor genes for enterotoxins A–Y were detected, but
the isolates harboured several staphylococcal enterotoxin-like toxin genes (set genes), as well as genes
encoding an epidermal cell differentiation inhibitor (edinB) and exfoliative toxin D (etD). Comparative
analysis of other isolates from Australia, Germany, Switzerland and the UK showed that these isolates
were representative of a widespread clone of caMRSA.
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INTRODUCTION
In recent years, strains of methicillin-resistant
Staphylococcus aureus (MRSA) have emerged that
carry the novel staphylococcal chromosome
cassette mec (SCCmec) type IV [1]. It was observed
that strains of this type are associated with
epidemic community-acquired disease [2–5],
while the previously known types (SCCmec types
I–III) were detected more usually in hospital
settings or in patients with a history of hospital-
isation. Outbreaks involving SCCmec type IV
strains have now been observed globally [4,6–
12]. This development raises serious concern,
especially as some SCCmec type IV strains pro-
duce a potent toxin, Panton–Valentine leukocidin
Corresponding author and reprint requests: S. Monecke,
Institute for Medical Microbiology and Hygiene, Faculty of
Medicine ‘Carl Gustav Carus’ at the Technical University of
Dresden, Fetscherstrasse 74, D-01307 Dresden, Germany
E-mail: monecke@rocketmail.com
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
(PVL), which is responsible for unusual virulence.
This toxin comprises two distinct components,
which together form pores in leukocytes [13].
PVL-producing strains can cause complicated
chronic deep-skin infections, or necrotising pneu-
monia with an extremely high mortality, even in
young and previously healthy patients [3–6,14–
17]. Cases of necrotising fasciitis caused by com-
munity-acquired MRSA (caMRSA) have also been
reported [18].
At present, it seems that different clonal groups
of caMRSA have evolved and spread simulta-
neously, resulting in a complex epidemiological
picture [19–21]. The situation is made even more
complicated by human migration [22], and by the
fact that many cases remain undiagnosed, as
specimens from community-acquired cases are
subjected only rarely to molecular characterisa-
tion [21]. The concomitant presence of PVL-
negative SCCmec type IV strains additionally
complicates diagnosis, as there are no reliable
phenotypic markers for PVL production. Diag-
nostic procedures are needed that allow the
detection of PVL-positive caMRSA strains, as well
as their assignment to clonal groups, in order to
monitor epidemiological developments. DNA
microarray hybridisation can be employed to
screen isolates for relevant resistance genes and
virulence factors [23,24].
The present study describes the occurrence of
case clusters and sporadic infections with a PVL-
positive strain of caMRSA. Diagnostic microarray
analysis and different PCR methods were used for
molecular characterisation of this strain. Addi-
tionally, a novel plasmid harbouring the resist-
ance determinants far1, tetK and blaZ was
characterised and partially sequenced.
MATERIALS AND METHODS
Case histories
Patient I was an otherwise healthy male aged 34 years from
eastern Saxony who was a member of a police force and had
been on a peacekeeping mission to Kosovo in 2003–2004. He
suffered from recurring furunculosis affecting the hands, legs
and buttocks. The condition probably started while he was in
Kosovo, but no other members of the force were known to
have been affected. The patient visited a surgical outpatient
department on several occasions during summer 2004, when
the furuncles were incised and irrigated with hydrogen
peroxide. However, no antimicrobial chemotherapy was
given, and no screening or isolation procedures were per-
formed as the patient had been discharged before the labor-
atory reports were received.
Patient II was a female aged 28 years who was the spouse of
patient I and who also served in the police force. She had not
been to Kosovo, but had travelled to Italy to attend a sports
contest. Suffering from recurrent furunculosis, she also pre-
sented on several occasions to a surgical ward for incision and
irrigation. In October 2004, both patients were admitted to a
dermatological ward. Several samples were obtained and,
following susceptibility testing, both patients received a
4-week course of oral levofloxacin and nasal mupirocin
ointment. By November 2004, both patients were free of
symptoms and nasal carriage was no longer detected.
A second case cluster occurred in a neighbouring region of
southern Brandenburg during 2005. In May 2005, a nurse aged
31 years (patient III) presented with an axillary abscess. She
recalled that her symptoms probably started while she was on
vacation to Austria and Bavaria. MRSA was detected, but the
isolate was unavailable for further study. In June 2005, a knee
abscess was diagnosed, but no isolate was available. An isolate
from a nasal swab was found to be PVL-positive. The patient
was treated with ciprofloxacin, and patients at the nursery
home where she worked were screened by the public health
authorities. Several MRSA strains were isolated from some of
her patients, but these isolates were PVL-negative. Her
husband (patient IV) had chronic nuchal furunculosis, com-
plicating a long-standing atopic dermatitis. Isolates were
unavailable for testing, but caMRSA was detected in a nasal
swab taken during July 2005. In late May 2005, a male co-
worker of patient IV, aged 31 years (patient V), was treated for
a groin abscess, which was incised and irrigated. The uncle of
patient V, aged 61 years (patient VI), suffered from a putrid
effusion of the knee. Identical caMRSA strains were isolated
and characterised from patients V and VI.
Patient VII, a male aged 54 years, was treated regularly for
a severe diabetic food syndrome, but no MRSA infection had
been detected previously. In summer 2004, he was admitted
with bacteraemia caused by Klebsiella spp. As he also suffered
from tracheobronchitis, sputum samples were taken and a
PVL-positive MRSA strain was cultured. The same strain was
also found in surveillance stool samples and rectal swabs. The
patient was treated with linezolid and mupirocin, resulting in
eradication of caMRSA. Later, the patient was colonised by
another strain of MRSA that was PVL-negative.
Patient VIII, a male aged 66 years, was treated in a long-
term rehabilitation centre because of an infarction of the right
middle cerebral artery. He had no symptoms that might have
been related to a S. aureus infection. Between March and June
2004, asymptomatic nasal carriage of caMRSA was detected.
This patient had family ties to a region in Bavaria where
outbreaks of caMRSA had been observed [21], and was
hospitalised in this region during 2000, i.e., before the known
outbreaks. Patients VII and VIII may have been in contact, as
they had been treated in the same rehabilitation centre.
However, the caMRSA isolates differed with respect to
plasmid carriage and spa type (see below).
Isolates
The bacterial isolates from patients I, II and IV–VIII were
available for susceptibility tests, SmaI macrorestriction analy-
sis, and diagnostic microarray hybridisations. An abscess
isolate from patient I (DD04V16073) obtained during May 2004
was used for characterisation and partial sequencing of the
resistance plasmid.
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Specimens taken from patients were spread on Columbia
blood agar (Oxoid, Wesel, Germany) and incubated overnight
at 37C. Single colonies were picked for further subculturing.
Reference strains (including the completely sequenced strains
MW2, Mu50, N315, Sanger 252, Sanger 476 and COL) and
additional sequence type (ST)80 strains were acquired from
various sources (see Acknowledgements).
Phenotypic characterisation and susceptibility testing
Tests for clumping factor and coagulase were performed with
a Pastorex Staph-Plus kit (Bio-Rad, Munich, Germany) and
rabbit plasma (Becton-Dickinson, Heidelberg, Germany). Rout-
ine susceptibility tests were performed using the VITEK I
system (bioMe´rieux, Nu¨rtingen, Germany) as recommended
by the manufacturer, with broth dilution conforming to
German standards (DIN58940-4). Fusidic acid resistance was
determined by disk-diffusion tests (10-lg disk; Oxoid).
Preparation of genomic DNA
Staphylococci were grown on Columbia blood agar. Two
inoculation loops of culture material were suspended in
100 lL of lysis solution containing 0.05 mg of lysostaphin
(Sigma, Steinheim, Germany), 2 mg of lysozyme (Sigma), 2 mg
of ribonuclease A (Sigma), 2 lL of 20 mM Tris-HCl, pH 8.0,
2 lL of 2 mM EDTA and 1 lL of Triton X-100. The suspension
was incubated on a shaker (45 min at 37C at 300 rpm). Then,
10 lL of proteinase K solution and 100 lL of buffer AL (both
from the Qiagen DNeasy kit; Qiagen, Hilden, Germany) were
added. After incubation for 45 min at 56C, the sample was
processed using the Qiagen EZ1 device and the tissue lysis
protocol supplied by the manufacturer.
Plasmid preparation
Plasmid DNA was isolated using the Qiagen Plasmid Midi Kit
according to a supplementary protocol provided by the manu-
facturer (http://www1.qiagen.com/literature/protocols/pdf/
QP10.pdf). Initially, staphylococcal cells were digested using
lysostaphin. Subsequently, plasmid preparation was performed
following the instructions in the kit. As this protocol was unable
to separate plasmid DNA completely from genomic DNA,
plasmid preparations for microarray hybridisation experiments
were subjected to non-denaturing agarose gel electrophoresis,
followed by ethidium bromide staining. The band correspond-
ing to the plasmid DNA was cut from the gel, and the plasmid
DNA was extracted using the HSB-Elutor E 51 (Biometra,
Go¨ttingen, Germany) according to the manufacturer’s protocol.
PCR
Several PCRs were employed for comparative analysis of the
plasmids in an isolate obtained from patient 1 (DD04V16073)
and the pUB101 reference strain WBG1576 [25]. Primers were
designed using the PrimerDesign software package (CLON-
DIAG chip technologies, Jena, Germany) from the plasmid
sequence (GenBank ID NC_005127) published by O’Brien et al.
[25]. Primer pairs designed to recognise far1 were primer pair
far1-A, 5¢-ACATATTTAAAGCTATTGGATCTTGA ⁄ 5¢-ACA-
ATTTTCACAAACATAGTTTATTCC, and primer pair far1-B,
5¢-ACAATGAAAACAATGATTTATCCT ⁄ 5¢-ACAATCACAA-
TTTTCACAAACA. Primer pairs used to detect cadD were
5¢-GCTCAACGTCAATAAAGCA ⁄ 5¢-CCTCATGTACACAGA-
TCACA and 5¢-GCTTTATGTTTTCGACTGTG ⁄ 5¢-CACAGAT-
CACATCACAAGC. Primers designed to detect ORF152 of
pUB101 (nt 18 348–18 806 in GenBank NC_005127) were
5¢-GCTTATTGTTGGAGGTGCT and 5¢-AGGGTCATAAATA-
CTCATTCCC. Additional primers bridging far1 and blaZ
(5¢-GGAATAAACTATGTTTGTGAAAATTGT ⁄ 5¢-ACAACTG-
TAATATCGGAGGG) and far1 and tetK (5¢-TCAAGATCCAA-
TAGCTTTAAATATGT ⁄ 5¢-AGCCACTCATAGTTCTAAACC)
were designed to check whether these genes were situated in
proximity and transcribed in the same direction. PCR was
performed with 19.6 lL of distilled water, 2.5 lL of 10· PCR
buffer (with a final concentration of 1.5 mM MgCl2), 0.5 lL of
dNTPs (200 lM), 0.5 lL of each primer (10 lM), 0.4 lL of Taq
polymerase (5 U ⁄lL) (all reagents from Promega, Madison,
WI, USA) and 0.1 lg of extracted staphylococcal DNA. PCRs
comprised 3 min at 94C, followed by 40 cycles of 95C for
60 s, 53C for 60 s and 72C for 60 s, with a final extension
period at 72C for 10 min. The amplification products were
checked by electrophoresis on agarose 1% w ⁄v gels and
ethidium bromide staining.
Microarray-based genotyping
DNA microarrays based on the Array-Tube platform (CLON-
DIAG chip technologies) were used for genotyping of sta-
phylococcal DNA. The microarrays were manufactured and
processed as described previously [24,26,27]. Probes were
printed on the array in two-fold redundancy.
A set of probes covering constitutive genes of S. aureus
(species markers), antibiotic resistance determinants and tox-
ins has been described and evaluated previously [24]. For the
present study, the array was extended to include all exotoxins
for which sequences were available. Furthermore, probes to
discriminate the allelic variants of the accessory gene regulator
(agr) gene cluster were added. The targets covered are
summarised in Table 1; a complete list of the probes and
probe sequences is given in Table S1 (see Supplementary
Material). The microarray was evaluated by running hybrid-
isation assays with DNA from S. aureus strains that have been
fully sequenced (MW2, Mu50, N315, Sanger 252, Sanger 476
and COL). The hybridisation patterns obtained were in full
accordance with the published sequence data [1,28–30]. The
results for the reference strain MW2 (GenBank accession
BA000033.2) are shown in Table 1. Data for the other strains
are not shown, but are available from the authors on request.
The protocol used for amplification and labelling of target
DNA is based on a protocol described previously [31] that has
been adapted for diagnostic microarrays. A detailed descrip-
tion has been published elsewhere [26,27]. In a first amplifi-
cation step, a large number of arbitrary extension products are
generated from the sample DNA (0.2–1.5 lg) in a primer
extension reaction. A primer containing a randomised octa-
meric sequence at the 3¢-end and an invariant sequence at the
5¢-end was used. In a second step, the extension products were
re-amplified in a PCR using the defined 5¢-sequence as the
target region for a biotinylated primer. Contrary to the
published protocols, amplicons from this reaction were used
directly for microarray hybridisation, as the use of a biotinyl-
ated primer made a third amplification step incorporating
biotin-labelled dUTP redundant.
The products from the amplification and labelling
procedures were hybridised to the microarray as described
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Table 1. Probes and hybridisation results for the sequenced community-acquired methicillin-resistant Staphylococcus
aureus strain MW2, the patient isolates, and a plasmid preparation from the patient I isolate
Target class Target
DNA preparation from
sequenced strain MW2
DNA preparations from
patient isolates
Plasmid DNA preparation
from patient I isolate
Genus marker 23S rRNA + + –
Species-specific markers femA + + –
gapA + + –
katA + + –
coa + + –
spa + + –
sak + + –
agr typing agrB type I – – –
agrC type I – – –
agrD type I – – –
agrD type I – – –
agrD type I – – –
agrB type II – – –
agrC type II – – –
agrD type II – – –
agrB type III + + –
agrC type III + + –
agrD type III + + –
agrB type IV – – –
agrC type IV – – –
Antibiotic resistance determinants blaZ + + (patient VIII isolate: )) +
mecA + + –
ermA – – –
ermC – – –
linA – – –
msrA – – –
vatA – – –
vatB – – –
vga – – –
Variant vga – – –
vgb – – –
aacA–aphD – – –
aadD – – –
aphA3 – + –
sat – + –
dfrA – – –
far1 – + (patient VIII isolate: )) +
mupR – – –
tetK – + (patient VIII isolate: )) +
tetM – – –
vanA – – –
vanB – – –
vanZ – – –
Superantigenic toxins tst1 – – –
entA + – –
entB – – –
entC + – –
entD – – –
entE – – –
entG – – –
entH + – –
entI – – –
entJ – – –
entK + – –
entL + – –
entM – – –
entN – – –
entO – – –
entQ + – –
entR – – –
entU – – –
Enterotoxin homologue + + –
entY + – –
c-haemolysin and bi-component toxins lukF + + –
lukS + + –
hlgA + + –
lukF-PVL + + –
lukS-PVL + + –
lukD + + –
lukE + + –
Putative leukocidin F subunit + + –
Putative leukocidin S subunit + + –
lukF-PVL-P83 – – –
lukM – – –
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previously [24,26,32]. Unbound DNA was removed by repea-
ted washing. The bound target DNA was conjugated with
streptavidin-coupled horseradish peroxidase and spots were
stained by peroxidase-mediated precipitation of 3, 3¢, 5, 5¢-
tetramethylbenzidine (TMB). An ATR01 Array-Tube reader
and the Iconoclust software package (CLONDIAG chip
technologies) were used for detection and analysis of the
hybridisation patterns according to the manufacturer’s recom-
mendations.
Typing methods
Pulsed-field gel electrophoresis (PFGE), following SmaI macro-
restriction, and spa typing were performed according to
previously described protocols [33,34] (http://www.ridom.
de/staphtype/).
Sequencing
Primers specific for blaZ (5¢-ACAACTGTAATATCGGAGG-
GT ⁄ 5¢-TCGAAAATAATAGAGGGAAAATCAG), far1 (primer
pair A, see above) and the region between far1 and blaZ (see
above) were used to amplify stretches of purified plasmid
DNA. The amplicons were inserted into cloning vector
pCR2.1-TOPO (Invitrogen). Recombinants were sequenced
using the BigDye Terminator Cycle Sequencing Ready Reac-
tion Kit (Applied Biosystems, Darmstadt, Germany) and an
ABI PRISM 310 Genetic Analyser (Applied Biosystems)
according to the manufacturer’s instructions.
RESULTS
Molecular typing
Hybridisation patterns for the agr-specific probes
indicated that all isolates belonged to agr type III.
SmaI macrorestriction and PFGE showed a pat-
tern identical to that of a caMRSA clonal group
from Germany, France and Switzerland, designa-
ted previously as SCCmec IV, multilocus ST80
[12]. Isolates from patients I, V and VIII were
found to belong to spa type 44, which was also in
agreement with ST80 (http://www.ridom.de/
spaserver/mlst.shtml). The isolate from patient
VII belonged to spa type 131.
Susceptibility testing and presence of genes
conferring resistance to antibiotics
All isolates were resistant to oxacillin and were
shown to carry the mecA gene in microarray
hybridisation experiments. They did not carry the
ermA, ermC, linA or msrA genes (complete hybrid-
isation data are shown in Table 1), which agreed
with the phenotypic susceptibilities to erythro-
mycin and clindamycin. The isolates were also
susceptible to levofloxacin and vancomycin. The
aphA3 and sat genes, conferring resistance to
neomycin and streptothricin, were detected by
microarray hybridisation, but susceptibility test-
ing for these compounds was not performed.
Neither the mupR gene nor a phenotypically high
level of mupirocin resistance was detected.
Isolates were usually intermediately- or fully-
resistant to fusidic acid and tetracycline. Micro-
array hybridisation experiments with DNA
Table 1. Continued
Target class Target
DNA preparation from
sequenced strain MW2
DNA preparations from
patient isolates
Plasmid DNA preparation
from patient I isolate
Other haemolysins hla + + –
hlb + + –
hld + + –
hlIII + + –
Unnamed haemolysin + + –
Exfoliative toxins etA – – –
etB – – –
etD – + –
Proteases splA + + –
splB + + –
Epidermal cell differentiation inhibitors edinA – – –
edinB – + –
edinC – – –
Staphylococcal exotoxin-like proteins set1 + + –
set2 + – –
set3 + + –
set4 + + –
set5 + + –
set6 as in MW2 and Sanger 476 + – –
set6 as in COL – + –
set7 + + –
set8 + + –
set9 + + –
set12 + + –
set21 + – –
setB + + –
setC + + –
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preparations from these isolates showed the
presence of the far1 and tetK genes. These two
genes, as well as a gene encoding a b-lactamase
(blaZ), were located on a plasmid (see below). The
isolate from patient VIII was susceptible to both
fusidic acid and tetracycline, and did not harbour
far1, tetK or blaZ.
Characterisation of a fusidic acid resistance
plasmid
PCR primers were designed to recognise far1 and
two other genes (cadmium resistance, cadD, and a
region designated ORF152) known to be situated
on plasmid pUB101 [25]. Two different PCRs for
the detection of far1 yielded amplicons of the
expected length (c. 790 bp) with the pUB101
reference strain WBG1576 [25], as well as with
the isolate from patient I. PCRs for cadD and
ORF152 were negative with the isolate from
patient I, showing that the plasmid from the
isolate was not identical to pUB101. When a
plasmid preparation was used instead of genomic
DNA for hybridisation with the DNA microarray,
positive signals were obtained with probes for
far1, tetK and blaZ (Table 1). A pair of primers
covering both far1 and blaZ yielded a product of
c. 2000 bp that was significantly shorter than the
product from WBG1576 (c. 2700 bp). PCR using
the primer pair bridging far1 and tetK (product
length of c. 6000 bp) also indicated the presence
of these genes on the plasmid (Fig. 1).
A 2917-bp fragment (Fig. 1) from the new
fusidic acid resistance plasmid was sequenced
(Fig. S1; see Supplementary Material) and alloca-
ted the GenBank accession number DQ269019.
The sequence obtained was very similar, but not
identical, to that of pUB101 (GenBank accession
number AY373761.1). Therefore, the designation
pUB102 was used for the remainder of this work.
The region sequenced contained the fusidic
resistance gene far1, whose sequence was com-
pletely identical to that of far1 from pUB101. It
also contained the blaZ b-lactamase gene and the
complete sequence of an insertion element des-
cribed as IS431 [35]. The sequences of the blaZ and
IS431 loci were identical to that of pUB101. In
both plasmids, IS431 was located downstream of
the coding sequence of blaZ. In pUB102, the inter-
genic region between the 3¢-end of blaZ and IS431
(left terminal repeat) was 24 bp long, which is
13 bp longer than in pUB101. This 24-bp sequence
downstream of blaZ is present in all blaZ genes
from S. aureus described previously, except
pUB101, where it has shortened to 11 bp. Com-
pared to pUB101, the new sequence showed a
deletion of 845 bp immediately downstream of
IS431 that removed a part of the region designa-
ted previously as ORF152 [25]. This deletion also
included one primer-binding site for the ORF152
PCR, and thus explained the negative PCR result
with DNA from the patient isolate. Otherwise, the
inter-genic sequences between IS431 and the far1
gene were identical in pUB101 and pUB102.
Genes encoding exotoxins
Microarray hybridisation data are summarised in
Table 1. All isolates contained the genes for both
PVL components (lukF-PVL and lukS-PVL). They
also harboured additional bi-component leukoci-
din genes (lukD and lukE), as well as a complete
Fig. 1. Partial structure of the new
fusidic acid resistance plasmid
showing the 2917-bp region that
was sequenced.
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hlg locus comprising lukS, lukF and hlgA. Another
putative bi-component leukocidin homologue
gene was also detected. Its sequence was annota-
ted either as leukocidin homologue or as ‘hypo-
thetical protein, similar to leukocidins’ in the
completely sequenced strains Mu50 (accession
number NC_002758; locus tags SAV2004 and
2005), N315 (NC_002745; SA1812 and 1813),
MW2 (NC_003923; MW1941 and 1942), MSSA476
(NC_002953; SAS1924 and S1925), MRSA252
(NC_002952; SAR2107) and COL (NC_002951;
SACOL2004 and 2005).
Genes for a- and d-haemolysins (hla and hld)
were present, and the gene for b-haemolysin (hlb)
was also detected. However, negative CAMP
factor test results with Streptococcus agalactiae
demonstrated that b-haemolysin was not pro-
duced, perhaps because of inactivation of the
gene by phage insertion [36]. Genes for the
epidermal cell differentiation inhibitor B (edinB)
and the exfoliative toxin D (etD) were also
detected in microarray hybridisation experiments.
The isolates did not contain any of the genes for
enterotoxins A–Y, but a hybridisation signal was
detected with a probe for a putative enterotoxin
gene matching the ‘enterotoxin homologues’ from
fully sequenced strains Mu50 (SAV1601), N315
(SA1429) and MW2 (MW1552), as well as the
sequences of ‘putative enterotoxins’ from strains
MRSA252 (SAR1679), MSSA476 (SAS1538) and
COL (SACOL1657).
Comparison with strain MW2 and other ST80
isolates
For comparison, the sequenced strain MW2 (NA-
RSA123), which belongs to spa type 131 [37,38], was
also tested. Data from this microarray hybridisa-
tion experiment are also presented in Table 1. The
results were in accordance with the previously
published genome of MW2 [1]. In contrast to MW2,
the ST80 isolates contained resistance genes aphA3,
far1, sat and tetK, as well as two additional viru-
lence factors (edinB and etD). They did not harbour
enterotoxin genes entA, entC, entH, entK, entL, entQ
and entY, and there were minor differences in set
gene carriage (Table 1).
ST80 isolates were obtained from other labor-
atories in order to compare them by microarray
analysis with the patient isolates from Saxony and
Brandenburg. One isolate from the UK [19], one
isolate from Switzerland and an ST583-MRSA-IV
isolate from Australia yielded identical hybridi-
sation results. Two other isolates, one from
Bavaria and one from Switzerland, differed only
by carriage of the clindamycin ⁄ lincomycin resist-
ance determinant linA.
DISCUSSION
The recent emergence of highly virulent, PVL-
carrying caMRSA is a cause for serious concern.
These strains are associated with chronic or
recurrent furunculosis, soft-tissue infections, and
abscesses. PVL-positive strains can also cause life-
threatening conditions, such as necrotising pneu-
monia [14] or necrotising fasciitis [18]. These
strains also have the potential for spread, as
highlighted by the case clusters described in the
present study. Therefore, methods for rapid iden-
tification and typing are crucial for an effective
therapeutic approach and containment.
SCCmec type IV strains are usually ‘less
multiresistant’ than typical hospital-acquired
MRSA strains. They are resistant to b-lactam
antibiotics, but are susceptible to most other
chemotherapeutic agents. Resistance genes that
are highly prevalent among hospital-acquired
MRSA strains [24], such as erm, aadD and aacA–
aphD genes, were not found in the ST80 patient
isolates in the present study. In addition to mecA,
the tested isolates carried only the aphA3, sat,
tetK and far1 genes. The aphA3 gene causes
resistance (MICs 32–128 mg ⁄L) to neomycin [24],
which is a drug used topically for skin and soft-
tissue infections. The sat gene is usually linked to
aphA3 [24], and a transposon has been sequenced
that contains both of these genes [39]. The sat
gene confers resistance to streptothricin antibiot-
ics, which are used only in veterinary medicine.
As fusidic acid is used commonly for the topical
treatment of staphylococcal skin infections,
resistance conferred by far1 is important clinic-
ally. The rarity of this property in strains other
than those belonging to ST80 means that fusidic
acid-resistant MRSA should be treated as PVL-
positive caMRSA [40] until proved otherwise.
Unfortunately, fusidic acid and tetracycline
resistance cannot be considered as reliable sur-
rogate markers for a putative identification of
PVL-carrying caMRSA. These resistance proper-
ties are plasmid-encoded, and characterisation of
the isolate from patient VIII proved that this
plasmid can be lost from clinical isolates.
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It is already known that the far1 gene is
plasmid-carried in S. aureus [12,25], but PCR
results showed that the plasmid in the present
study was different from the fusidic acid resist-
ance plasmid pUB101 described previously [25].
Differences included the presence of the tetra-
cycline resistance tetK gene and the absence of the
cadmium resistance cadD gene. Since the linkage
of IS431 was different at both ends of the insertion
element compared with pUB101, it can be
assumed that the new sequence is the result of a
different insertion event than that leading to the
formation of pUB101. Generally, plasmid carriage
within different isolates of the ST80 caMRSA
strain appears to be variable. This could explain
why other isolates were described as carrying far1
plus another tetracycline resistance determinant,
tetM [12], and why two isolates were found to
carry linA (see above).
The ST80 caMRSA isolates contained genes
encoding several bi-component toxins, i.e., lukF-
PVL plus lukS-PVL, lukD plus lukE, the hlg locus
composed of lukS, lukF, and hlgA, and yet another
bi-component leukocidin homologue. Moreover,
the isolates did not harbour genes for the toxic
shock syndrome toxin, or any enterotoxin except
for an enterotoxin homologue that has been found
in all S. aureus strains that have been sequenced
completely. Given the fact that many, possibly
most, virulent S. aureus strains produce multiple
enterotoxins [41,42], this is a remarkable finding.
The caMRSA isolates also contained the genes for
an epidermal cell differentiation inhibitor (edinB)
and exfoliative toxin D (etD). These two genes are
known to occur together, forming a pathogenicity
island [43]. The isolates also harboured several
genes from the staphylococcal enterotoxin-like
toxins (set) family. However, there is an absence
of published data concerning the clinical signifi-
cance of these toxins.
Microarray hybridisation has been used previ-
ously to screen isolates for relevant resistance
determinants and virulence factors. The proposed
technology [24,26,27,32], combined with the array
described in the present study, permits the sim-
ultaneous detection of 90 different genes that are,
except for some species-specific controls, associ-
ated with either virulence or resistance. In this
way, it was possible to identify isolates as PVL-
positive caMRSA within 24 h of primary culture,
and to obtain a dataset that allows easy compar-
ison of strains. Data from microarray hybridisa-
tions correlated well with SmaI PFGE and spa
typing. One isolate (from patient VII) showed a
distinct spa type, although its genetic profile, as
obtained by microarray analysis, was identical.
However, the two spa types observed were related
closely, differing only by duplication of one
repeating unit (spa type 131, 07-23-12-34-33-34;
spa type 44, 07-23-12-34-34-33-34; http://www.
ridom.de/spaserver/dynamic/spatypes.txt). The
similarity of these two spa types also allows a
phylogenetic relationship to be assumed between
the clinical ST80 isolates and the sequenced strain
MW2 [1], which also belongs to spa type 131
[37,38]. MW2 was isolated in North Dakota, USA,
in 1998 [44]. Compared to this strain [1], the ST80
strain had acquired a resistance plasmid (carrying
blaZ, far1 and tetK), two resistance genes known to
be located on a transposon (sat and aphA3), and a
pathogenicity island (edinB and etD), but had lost
several enterotoxin genes (A, C, H, K, L, Q and Y).
This loss of superantigenic enterotoxins contrasts
with the possession of several cytotoxic toxins
from the bi-component leukocidin class. Whether
this represents some kind of evolutionary trend
towards cytotoxicity should be clarified by testing
additional PVL-positive strains in order to find
the ‘missing links’ between MW2 and ST80, and
to investigate whether similar developments can
be observed in other lineages.
The geographical distribution and the spread
of the ST80 strain is also of great practical
importance. Microarray hybridisations were per-
formed with additional caMRSA isolates from
various sources. An Australian isolate gave
identical hybridisation results, although it was
identified as ST583. However, this is only a
single-locus variant of ST80 (identical to ST80slv
[20]; G. Coombs, personal communication).
Other isolates from Bavaria, Switzerland and
the UK [19] were identical in microarray experi-
ments, except for the presence of linA in two
isolates, which can be attributed to plasmid
carriage, as this gene is known to be plasmid-
borne [45]. Together with results from Denmark,
France, the UK, Greece, Norway [10,11,17,19,46–
48], the Middle East [22], and Turkey [22], these
findings suggest that global spread of this strain
has occurred. The travel histories of patients I
(Kosovo), II (Italy), III and VIII (Bavaria) initially
suggested an introduction of this strain by these
patients into eastern Saxony and southern Bran-
denburg, but indigenous infection could not be
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ruled out. While infections with this strain in
Germany were first recorded in the second half
of 2002 [40], its presence in this region was not
known before the diagnosis of patients I and II
in summer 2004. The histories of these two
patients are alarming, as their caMRSA infection
was not diagnosed for a lengthy period, despite
the fact that they were under medical observa-
tion. It can be assumed that other cases might
remain undiagnosed, especially in the outpatient
setting. Patients VII and VIII indicate that
asymptomatic carriage of this strain might also
occur, despite its enhanced virulence. The exist-
ence of such carriers and symptomatic, but
undiagnosed, cases is a major obstacle to any
quarantine and control measures. The high
virulence of this strain, accompanied by resist-
ance to first-line drugs, requires rapid diagnostic
measures to facilitate effective therapy and con-
tainment. In the absence of reliable phenotypic
traits (such as characteristic resistance patterns),
virulent caMRSA strains can be identified only
by molecular methods. The proposed DNA
microarray technology provides a valuable diag-
nostic tool for this task.
SUPPLEMENTARY MATERIAL
The following supplementary material is avail-
able for this article online at http://www.black-
well-synergy.com:
Table S1. Probes on the array and their se-
quences, as defined by accession number and
position
Fig. S1. Partial sequence of the new fusidic acid
resistance plasmid.
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